Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has earned an average recommendation of “Hold” from the nine research firms that are covering the firm. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $39.83.

Several equities research analysts have recently issued reports on ITCI shares. Piper Jaffray Cos. reissued an “overweight” rating and issued a $57.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, June 22nd. Leerink Swann reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 22nd. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Wednesday, June 29th. Cowen and Company reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 29th. Finally, SunTrust Banks Inc. lowered shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $60.00 to $15.00 in a research report on Thursday, September 29th.

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) traded up 0.61% during midday trading on Monday, reaching $13.11. 519,084 shares of the company were exchanged. Intra-Cellular Therapies has a 52-week low of $12.85 and a 52-week high of $59.96. The stock’s 50-day moving average price is $32.73 and its 200-day moving average price is $36.28. The company’s market capitalization is $567.02 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.08. The business earned $0.23 million during the quarter, compared to analyst estimates of $0.02 million. During the same period in the previous year, the company earned ($0.61) EPS. Intra-Cellular Therapies’s revenue was up 283.3% on a year-over-year basis. Analysts anticipate that Intra-Cellular Therapies will post ($3.19) EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at $155,000. Fox Run Management L.L.C. bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at $318,000. Iguana Healthcare Management LLC bought a new position in shares of Intra-Cellular Therapies during the first quarter valued at $1,347,000. Springbok Capital Management LLC bought a new position in shares of Intra-Cellular Therapies during the first quarter valued at $212,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Intra-Cellular Therapies during the first quarter valued at $1,480,000. 70.31% of the stock is owned by institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.